文章名稱引用次數(shù)

• Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study42
• Altered gut microbiota profile in patients with generalized anxiety disorder27
• Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility25
• Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial20
• A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer's disease20
• Predictors of long-term recovery in anorexia nervosa and bulimia nervosa: Data from a 22-year longitudinal study18
• Voltage-gated calcium channel activity and complex related genes and schizophrenia: A systematic investigation based on Han Chinese population16
• Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: A systematic review and meta-analysis16
• Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients15
• ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials14